Category North America

Quest For US Termination Of Copyright Made Uncertain By UK Duran Duran Judgment

Efforts to reclaim rights under the US Copyright Act have increased recently as the window of opportunity for works created in the mid-20th century opens. In comparative cases, Paul McCartney's decision to take back copyright assignments of his music in the United States appears to have been the right choice but may hang on a questionable UK ruling denying the same request by members of rock group Duran Duran, several intellectual property lawyers said.

Year Ahead: A Rather Speculative Year In Global Trade

An interesting year lies ahead for trade policymakers. With US President Donald Trump sticking to his “America First” announcement pulling back from the Trans-Pacific Partnership right away, a new trade (world) order might be in the making. In every crisis, there is opportunity, Argentinian Trade Minister Susana Malcora said in Davos during the January World Economic Forum (WEF) where the business elite otherwise traded concerns at the beginning of an unpredictable year 2017.

A Case For Trade Enforcement: Colombia And Intellectual Property

President Trump and members of his administration have rightly talked about the need to be tougher on trade enforcement, including promising to take a closer look at existing trade agreements to see whether they should be revoked, renegotiated, or more strictly enforced. A candidate ripe for review is Colombia, and in particular, its ongoing failure to implement intellectual property provisions under the U.S. Colombia Trade Promotion Agreement (TPA), Nigel Corey writes.

IP Law In The US: A Look Ahead

Whatever else could be said of 2016, it was undeniably interesting. That’s likely to be true, too, for 2017. Even the staid area of US Intellectual Property Law may face dramatic changes. Here's the likely most important of those changes.

After 15 Years In WTO, China Still Weak On Many IP Rights Rules, US Says

Innovation and intellectual property rights have set the United States apart from competitors in recent history, and China seems intent on closing that gap any way it can. A US trade office report out this week on China’s compliance with World Trade Organization rules 15 years after accession show the magnitude of China’s continuing compliance problems related to intellectual property rights.

Expensive Medicines Increase The Pressure

When Gilead brought its new antiviral medicine – Sovaldi – for the treatment of Hepatitis C to the US market for USD 84,000, it triggered a storm of protest. Demand for this revolutionary treatment was so high that the price (despite reductions) became an enormous burden on the American healthcare system. Although the product is cheaper in Switzerland at CHF 48 307, treatment is rationed for reasons of cost.

US Food And Drug Administration Issues Equivalence Guideline For Biosimilars Producers

Biotherapeutic medicines are made out of living organisms and cannot be replicated. No generic medicines, which are exact copies of the reference product, can be made. The generic equivalent of a biotherapeutic would be biosimilars, which are highly similar products. The United States Food and Drug Administration has issued a guide to help producers to prove how close their biosimilars are to the biotherapeutics.